This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Kazia Therapeutics Croissance future

Future contrôle des critères 3/6

Kazia Therapeutics devrait augmenter ses bénéfices et son chiffre d'affaires de 49.6% et de 47.7% par an respectivement. Le BPA devrait croître de de 59.7% par an. Le rendement des capitaux propres devrait être 25% dans 3 ans.

Informations clés

49.6%

Taux de croissance des bénéfices

59.7%

Taux de croissance du BPA

Biotechs croissance des bénéfices	15.1%
Taux de croissance des recettes	47.7%
Rendement futur des capitaux propres	25.0%
Couverture par les analystes	Low
Dernière mise à jour	10 Aug 2023

Mises à jour récentes de la croissance future

Recent updates

We're Not Worried About Kazia Therapeutics' (ASX:KZA) Cash Burn

Jun 24

We're Not Worried About Kazia Therapeutics' (ASX:KZA) Cash Burn

Feb 24

We Take A Look At Why Kazia Therapeutics Limited's (ASX:KZA) CEO Compensation Is Well Earned

Nov 03

We Think Kazia Therapeutics (ASX:KZA) Can Easily Afford To Drive Business Growth

Sep 23

We Think Kazia Therapeutics (ASX:KZA) Can Afford To Drive Business Growth

May 04

When Will Kazia Therapeutics Limited (ASX:KZA) Turn A Profit?

Mar 27

Could The Kazia Therapeutics Limited (ASX:KZA) Ownership Structure Tell Us Something Useful?

Feb 28

What Can We Learn About Kazia Therapeutics' (ASX:KZA) CEO Compensation?

Feb 01

We Think Kazia Therapeutics (ASX:KZA) Can Afford To Drive Business Growth

Jan 06

Bullish: Analysts Just Made An Incredible Upgrade To Their Kazia Therapeutics Limited (ASX:KZA) Forecasts

Dec 11

Kazia Therapeutics Limited (ASX:KZA): When Will It Breakeven?

Nov 26

Prévisions de croissance des bénéfices et des revenus

ASX:KZA - Estimations futures des analystes et données financières antérieures (AUD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
6/30/2026	3	-17	N/A	N/A	1
6/30/2025	11	-6	7	7	2
6/30/2024	11	-7	7	7	2
6/30/2023	0	-20	-15	-15	N/A
3/31/2023	0	-23	-18	-18	N/A
12/31/2022	N/A	-25	-20	-20	N/A
9/30/2022	0	-25	-21	-21	N/A
6/30/2022	0	-25	-23	-23	N/A
3/31/2022	8	-20	-15	-15	N/A
12/31/2021	15	-15	-8	-8	N/A
9/30/2021	15	-12	-9	-9	N/A
6/30/2021	15	-8	-9	-9	N/A
3/31/2021	8	-11	-14	-14	N/A
12/31/2020	0	-13	-18	-18	N/A
9/30/2020	1	-13	-14	-14	N/A
6/30/2020	1	-12	-9	-9	N/A
3/31/2020	1	-11	-7	-7	N/A
12/31/2019	1	-10	-5	-5	N/A
9/30/2019	1	-10	-6	-6	N/A
6/30/2019	1	-10	-7	-7	N/A
3/31/2019	2	-11	-6	-6	N/A
12/31/2018	2	-12	-5	-5	N/A
9/30/2018	3	-9	-7	-7	N/A
6/30/2018	3	-6	-9	-9	N/A
3/31/2018	4	-6	-10	-10	N/A
12/31/2017	6	-6	-12	-12	N/A
9/30/2017	7	-8	-12	-12	N/A
6/30/2017	9	-11	-11	-11	N/A
3/31/2017	7	-12	N/A	-12	N/A
12/31/2016	5	-12	N/A	-12	N/A
9/30/2016	4	-12	N/A	-12	N/A
6/30/2016	3	-12	N/A	-12	N/A
3/31/2016	3	-10	N/A	-12	N/A
12/31/2015	3	-9	N/A	-12	N/A
9/30/2015	2	-8	N/A	-9	N/A
6/30/2015	2	-7	N/A	-6	N/A
3/31/2015	2	-7	N/A	-5	N/A
12/31/2014	2	-7	N/A	-5	N/A
9/30/2014	1	-7	N/A	-5	N/A
6/30/2014	0	-7	N/A	-6	N/A
3/31/2014	0	-6	N/A	-5	N/A
12/31/2013	1	-5	N/A	-3	N/A
9/30/2013	1	-3	N/A	-6	N/A
6/30/2013	1	-2	N/A	-9	N/A
3/31/2013	1	-1	N/A	-11	N/A
12/31/2012	1	1	N/A	-13	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: KZA devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: KZA devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: KZA devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de KZA ( 47.7% par an) devrait croître plus rapidement que le marché Australian ( 5.6% par an).

Croissance élevée des revenus: Le chiffre d'affaires de KZA ( 47.7% par an) devrait croître plus rapidement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de KZA devrait être élevé dans 3 ans ( 25 %)

This company listing is no longer active

Kazia Therapeutics Croissance future

Future contrôle des critères 3/6

Informations clés

Mises à jour récentes de la croissance future

Forecast to breakeven in 2024

Price target decreased to AU$0.45

No longer forecast to breakeven

No longer forecast to breakeven

No longer forecast to breakeven

Consensus forecasts updated

Recent updates

Kazia Therapeutics Limited Reports Successful Stage 1 Completion of the EVT801 Phase 1 Clinical Trial in Advanced Cancer Patients

Kazia Therapeutics Limited announced that it expects to receive $15 million in funding from Alumni Capital LP

Kazia Therapeutics Limited Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint

Kazia Therapeutics Limited Announces Appointment of Board Members

Kazia Therapeutics Limited Announces Executive Changes

Kazia Therapeutics Limited has completed a Follow-on Equity Offering in the amount of $1.981756 million.

Kazia Therapeutics Announces Receipt of Nasdaq Minimum Bid Notification

Kazia Therapeutics Provides Preliminary Update from Ongoing Phase 2 Study of Paxalisib in Primary Cns Lymphoma

New major risk - Market cap size

Kazia Therapeutics Limited Announces Clinical Data At ESMO 2023 from Ongoing Phase 1 ESMO Study

Kazia Therapeutics Limited Announces Acceptance of Late-Breaking Abstracts and Oral Presentation of Pnoc022 Clinical Data At 2023 Society for Neuro-Oncology Annual Meeting

Kazia Therapeutics Limited, Annual General Meeting, Nov 08, 2023

New minor risk - Financial data availability

Kazia Therapeutics Limited Announces Change to Board of Directors

Kazia Therapeutics Limited Announces Change to Board of Directors

Kazia Therapeutics Limited Appoints John Friend as Managing Director

Kazia Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 4.5 million.

Kazia Therapeutics Limited Receives Fast Track Designation from FDA for Treatment of Solid Tumor Brain Metastases Harboring PI3K Pathway Mutations in Combination with Radiation Therapy

High number of new and inexperienced directors

Kazia Therapeutics Limited Announces Phase II Clinical Study to Investigate Paxalisib in Recurrent/Progressive IDH-Mutant Grade 2 & 3 Glioma

Kazia Therapeutics Limited Appoints Ms. Ebru Davidson to its Board

Forecast to breakeven in 2024

Kazia Announces Receipt of Nasdaq Minimum Bid Notification

Kazia Therapeutics Announces the Publication of Pre-Clinical Data for Its Second Pipeline Asset, EVT801 in the Journal Cancer Research Communications

Kazia Therapeutics Limited Announces Publication of Positive Preclinical Data for Evt801

Price target decreased to AU$0.45

No longer forecast to breakeven

Kazia Therapeutics Limited's Paxalisib Demonstrates Positive Monotherapy Efficacy Signals in Preclinical Models of Melanoma

Kazia Therapeutics Limited Announces Expansion of PNOC Study into Australia

Kazia Therapeutics Limited, Annual General Meeting, Nov 16, 2022

No longer forecast to breakeven

Kazia Therapeutics Limited Presents Promising New Data from an Ongoing Phase I Clinical Trial of Paxalisib in Combination with Radiotherapy

No longer forecast to breakeven

Kazia Therapeutics Limited Provides Progress Update on GBM Agile Pivotal Study

Consensus forecasts updated

Kazia Therapeutics Limited Launches New Scientific Advisory Board

Kazia Therapeutics Limited Launches New Scientific Advisory Board

United States Food and Drug Administration Awards Rare Pediatric Disease Designation to Kazia Therapeutics Limited's Paxalisib for AT/RT, Rare Form of Childhood Brain Cancer

Kazia Therapeutics Limited Provides Progress Update on Paxalisib and EVT801 Clinical Programs

We're Not Worried About Kazia Therapeutics' (ASX:KZA) Cash Burn

Consensus forecasts updated

Kazia Therapeutics Limited Announces Phase II Study of Paxalisib in Brain Metastases Advances to Expansion Stage in Breast Cancer Brain Metastases Cohort

Kazia Presents Positive Final Data from Phase II Study of Paxalisib in Newly Diagnosed Glioblastoma at ASCO Conference

Kazia to Present Final Data from Paxalisib Phase II Study in Glioblastoma At ASCO

Insufficient new directors

Kazia Therapeutics Limited Announces Phase II Study of Paxalisib in Glioblastoma Achieves Final Completion

Kazia Presents Preclinical Data for Paxalisib At AACR

Consensus forecasts updated

Consensus forecasts updated

Kazia Therapeutics Limited Announces Phase II Clinical Study at Weill Cornell Medical Center Investigating Paxalisib in Combination with Metformin and a Ketogenic Diet Enrolls First Patient

Kazia Therapeutics Limited Announces First Patient Enrolls in Phase II Clinical Study Investigating Paxalisib in Combination with Metformin and a Ketogenic Diet

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

We're Not Worried About Kazia Therapeutics' (ASX:KZA) Cash Burn

Price target decreased to AU$1.90

Independent Non-Executive Director recently bought AU$54k worth of stock

Simcere Pharmaceutical Group Limited Announces Clinical Trial Approval for SIM0395 (Paxalisib) Issued by Thenational Medical Products Administration Under Collaboration with Kazia Therapeutics Limited

Kazia Releases Final Data from P2 Paxalisib Trial

No longer forecast to breakeven

We Take A Look At Why Kazia Therapeutics Limited's (ASX:KZA) CEO Compensation Is Well Earned

We Think Kazia Therapeutics (ASX:KZA) Can Easily Afford To Drive Business Growth

Full year 2021 earnings released: AU$0.072 loss per share (vs AU$0.17 loss in FY 2020)

Kazia Therapeutics Limited Provides Progress Update on Paxalisib and Evt801 Clinical Programs

Kazia Therapeutics Limited Announces Manufacturing Patents Granted for Paxalisib in Key Territories

Kazia Therapeutics Limited Launches New Paxalisib Phase II Clinical Trial

Kazia Therapeutics Limited Announces Study of Paxalisib in Primary CNS Lymphoma at Dana-Farber Cancer Institute Enrols First Patient

Consensus forecasts updated

We Think Kazia Therapeutics (ASX:KZA) Can Afford To Drive Business Growth

Consensus forecasts updated